Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ SLC29A3 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA566109
Description
Immunogen sequence: KEYWMFKLRNS SSPATGEDPE GSDILNYFE Highest antigen sequence identity to the following orthologs - mouse 80%, rat 80%.
SLC29A3 is a member of the equilibrative nucleoside transporter family which plays a key role in nucleoside and nucleobase uptake for salvage pathways of nucleotide synthesis. SLC29A3 is a transmembrane glycoprotein that localizes to the lysosomal membrane and is a broad selectivity, low affinity nucleoside transporter. Mutations in the SLC29A3 gene have been associated with H syndrome, which is characterized by cutaneous hyperpigmentation and hypertrichosis, hepatosplenomegaly, heart anomalies, and hypogonadism. A related disorder, PHID (pigmented hypertrichosis with insulin-dependent diabetes mellitus), has also been associated with mutations at this locus.
Specifications
SLC29A3 | |
Polyclonal | |
Unconjugated | |
SLC29A3 | |
4933435C21Rik; AW987637; Ent3; Equilibrative nucleoside transporter 3; HCLAP; hENT3; HJCD; mENT3; PHID; Slc29a3; solute carrier family 29 (equilibrative nucleoside transporter), member 3; solute carrier family 29 (nucleoside transporters), member 3; solute carrier family 29 member 3; UNQ717/PRO1380 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
55315 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Western Blot, Immunocytochemistry | |
0.05 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
Q9BZD2 | |
SLC29A3 | |
Recombinant Human SLC29A3. Recombinant protein control fragment (Product #RP-105085). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction